Not that the company is lying about the product but a PR job is to make anything sound really good.
I totally agree that Wittenberg is dead weight to the company and Dr. Moro has a lot of responsibility running the company AND doing the research. Small companies are between a proverbial rock and a hard spot in promoting their products. The test is NOT FDA approved for cancer so he has to be very careful what he says. He is definitely building the credibility of the test with Abbott finally saying something, but not very much, at the ISOBM. Right now, one of the problem with RECAF is that it does not point to the cancer so it is not a stand alone test. It will have to be paired with another test to confirm or prove false the results. If you notice, their is really a glut of cancer markers that have been proposed with only a few under testing. They are mostly all molecular and most do not really show you have cancer but that you may get cancer. RECAF is not molecular, DNA type test, but an assay to show the presence of a lot of receptors. It is a different concept and not a definitive yes/no test. There is a "grey area" around the cutoff that gives us the false negatives and positives for the test. If Abbott is waiting on perfection of the test to reduce that "grey area", I do not think they will be successful. The test they demonstrated at the ISOBM showed very good results.
I do think they could do some more effective PR to bring attention to the company for investors but the question remains, How do you best reach the investors. If you make a general PR campaign, then you end up with a lot of people with suspected cancer inquiring about the test and you cannot help them. The methods they have used in the past have not worked either so IMO, this is going to come down to Abbott making more progress or a new partner.
